Abstract
Cancer is the second leading cause of death globally, often due to the absence of early symptoms and late-stage diagnosis. Early detection remains the most effective strategy for improving survival rates, as early-stage cancers without metastasis are often curable. Biomarkers play a crucial role in disease identification, early diagnosis, and monitoring during treatment. This protocol details a systematic review and meta-analysis designed to evaluate the predictive value of Meprin A Subunit Alpha (MEP1A) as a diagnostic biomarker across multiple cancer types.
Introduction
The primary challenge in oncology remains the "holy grail" of early detection. Most cancers are significantly more treatable—and often curable—if identified before metastasis occurs. However, many malignancies lack obvious early symptoms, leading to high recurrence rates and late-stage intervention. While MEP1A, a metalloprotease involved in various biological processes, has been identified as a potential biomarker for cancer identification, conflicting results across primary studies necessitate a rigorous synthesis of evidence. This protocol addresses the need to quantify the sensitivity, specificity, and overall predictive value of MEP1A through a high-level meta-analysis.
Methodology
This study follows a structured protocol for systematic review and meta-analysis to ensure clinical utility and reliability.
Search Strategy and Data Sources
The researchers will perform a comprehensive search of both international and regional databases to ensure a broad evidence base:
- PubMed and Cochrane Library for international peer-reviewed literature.
- China National Knowledge Infrastructure (CNKI) and Chinese Biomedical Literature Database (CBM) to capture significant regional research that is often overlooked in Western-centric analyses.
Inclusion Criteria and Quality Assessment
The review will include randomized controlled trials, cohort studies, case-control studies, and cross-sectional studies comparing MEP1A levels in cancer patients against healthy controls. To ensure the reliability of the synthesized data, the QUADAS-2 tool will be employed to assess the quality of diagnostic accuracy studies. Studies with a high risk of bias will be excluded from the final synthesis.
Statistical Analysis
The DerSimonian-Laird method (a random-effects model) will be used to pool estimates of sensitivity and specificity. The overall diagnostic performance will be visualized using Summary Receiver Operating Characteristic (sROC) curves, providing a clear picture of MEP1A's diagnostic accuracy.
Significance and Scope
A key strength of this protocol is its pan-cancer scope. Unlike studies restricted to a single organ, this analysis will encompass a wide array of common tumors, including gastric, lung, colorectal, esophageal, liver, breast, cervical, prostate, and ovarian cancers. This approach aims to determine if MEP1A serves as a versatile biomarker across different organ systems.
To maintain analytical rigor, the researchers will:
- Use the $I^2$ statistic to measure and manage heterogeneity between studies.
- Perform subgroup and sensitivity analyses if $I^2 > 50\%$ to investigate discrepancies in results (e.g., due to cancer type or study quality).
- Apply Egger’s test to detect potential publication bias, ensuring that the meta-analysis provides an objective assessment of MEP1A’s effectiveness rather than just highlighting "positive" results.
Limitations and Future Directions
The primary limitation of this study is its language restriction to English and Chinese publications. While these databases are extensive, relevant research in other languages may be excluded. As this document represents a research protocol, the actual data collection and quantitative results are pending. Upon completion, the findings will indicate whether MEP1A is a viable candidate for clinical validation trials and the potential development of non-invasive diagnostic tests.
Summary updated